Fibromyalgia Therapeutic Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical/Non-Clinical Trial Activities, Emerging Therapies, and Key Companies by DelveInsight

As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Fibromyalgia therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Fibromyalgia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Fibromyalgia Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Fibromyalgia Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Fibromyalgia Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fibromyalgia treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Fibromyalgia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Fibromyalgia Therapeutics Analysis
Fibromyalgia is a long-term (chronic) condition that can cause pain in the muscles and bones (musculoskeletal pain), areas of tenderness, general fatigue, and sleep and cognitive disturbances. The U.S. Food and Drug Administration has approved three drugs to treat fibromyalgia. They include two drugs that change some of the brain chemicals (serotonin and norepinephrine) that help control pain levels: duloxetine (Cymbalta) and milnacipran (Savella).

The other drug approved for fibromyalgia is pregabalin (Lyrica). Pregabalin and another drug, gabapentin (Neurontin), work by blocking the overactivity of nerve cells involved in pain transmission. These medicines may cause dizziness, sleepiness, swelling, and weight gain. To further improve the treatment scenario, globally, several key companies are actively working in the therapeutics market.

As per DelveInsight's assessment, there are approx. 15+ key companies which are developing therapies for Fibromyalgia. Currently, Tonix Pharmaceuticals is leading the therapeutics market with its Fibromyalgia drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Fibromyalgia Therapeutics Market Include
- Tonix Pharmaceuticals
- Aptinyx
- Virios Therapeutics, Inc.
- Teva Pharmaceuticals
- Knop Laboratorios
- ntegrated Tissue Dynamics, LLC
- Axsome
- Sorrento Therapeutics
- Imbrium Therapeutics
- Cytocom Inc.
- Cortene Inc.
- Intec Pharma
- Luye Pharma
And Many Others.

Fibromyalgia Emerging Drugs Covered in the Report Include:
- IMC1: Virios Therapeutics
- TNX-102: Tonix Pharmaceuticals
And Many More

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Fibromyalgia Current Treatment Patterns
4. Fibromyalgia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Fibromyalgia Late-Stage Products (Phase-III)
7. Fibromyalgia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fibromyalgia Discontinued Products
13. Fibromyalgia Product Profiles
14. Fibromyalgia Key Companies
15. Fibromyalgia Key Products
16. Dormant and Discontinued Products
17. Fibromyalgia Unmet Needs
18. Fibromyalgia Future Perspectives
19. Fibromyalgia Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.